-
Analyst: Peak Sales Potential Of Amarin's Vascepa Underappreciated
Friday, November 15, 2019 - 4:04pm | 526Read More...Amarin Corporation (NASDAQ: AMRN) traded higher after the FDA's Endocrinologic and Metabolic Drug Advisory Committee voted 16-0 to recommend approval of label expansion for Vascepa capsules to include reduction in the risk of cardiovascular, or CV, events in high-risk patients. Vascepa is the...
-
Amarin Shares Climb Following In-Line Review Of Fish Oil Pill By FDA Staffers
Tuesday, November 12, 2019 - 12:28pm | 556Read More...Amarin Corporation plc (NASDAQ: AMRN) shares were climbing to a 3-1/2 month high Tuesday after the FDA posted a briefing document ahead of an Adcom meeting on Amarin's fish oil capsule Vascepa that's scheduled for Thursday. Vascepa, or icosapent ethyl, was previously...
-
Mylan's Disappointing Outlook Rattles Analysts, Investors
Wednesday, February 27, 2019 - 5:04pm | 758Read More...Mylan NV (NASDAQ: MYL) reported disappointing fourth-quarter earnings Tuesday and forecast an earnings shortfall for 2019. The Analysts BMO Capital Markets analyst Gary Nachman maintained an Outperform rating on Mylan shares and reduced the price target from $44 to $40. Cantor Fitzgerald...
-
Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts
Tuesday, March 13, 2018 - 4:32pm | 783Read More...Biotech stocks are at the mercy of market-moving catalysts, and Cantor Fitzgerald analyst Louise Chen outlined potential outlined potential stock-moving events for eight biotech names in a Monday report. Mylan: Pipeline Update, Patent Challenge Mylan N.V. (NASDAQ: MYL) is scheduled to hold...
-
Analyst: Why The Sucampo Deal Is A Smart Move For Mallinckrodt
Tuesday, December 26, 2017 - 4:54pm | 455Read More...Mallinckrodt PLC (NYSE: MNK) announced an agreement Tuesday to buy Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) for $1.2 billion. The Analyst Cantor Fitzgerald analyst Louise Chen has an Overweight on Mallinckrodt with a $42 price target. The Thesis The Sucampo transaction is a smart...
-
Valeant Investors: Cantor Says It's Time To Stop Waiting For The Other Shoe To Drop
Thursday, June 29, 2017 - 8:50am | 403Read More...Analysts at Cantor Fitzgerald turned incrementally bullish on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) after the once-troubled pharmaceutical company is showing signs of sustaining momentum. Cantor Fitzgerald's Louise Chen maintains an Overweight rating on Valeant's stock with a price...
-
UPDATE: Guggenheim Securities Reiterates on Cadence Pharmaceuticals as Earnings Visibility for Ofirmev Improves
Tuesday, December 3, 2013 - 11:43am | 131Read More...In a report published Tuesday, Guggenheim Securities analyst Louise Chen reiterated a Buy rating on Cadence Pharmaceuticals (NASDAQ: CADX), and raised the price target from $9.00 to $15.00. In the report, Guggenheim Securities noted, “We arrive at our new 12-month PT of $15 by using a blend of P/E...
-
Johnson & Johnson (JNJ) Woes Benefit Perrigo (PRGO)
Monday, May 3, 2010 - 9:36am | 181Read More...Collins Stewart analysts Louise Chen and Swati Kumar reiterated their Buy rating and $73 price target for shares of Perrigo Company (NASDAQ: PRGO). Chen and Kumar said that the recall of various infants' and children's products by Johnson & Johnson (NYSE: JNJ) will benefit Perrigo Company. The...
-
Teva Pharmaceuticals Industries Ltd. (TEVA) Quarterly EPS Estimates For 2010 Revised
Wednesday, February 17, 2010 - 12:21pm | 130Read More...Analysts Louise Chen and Swati Kumar at Collins Stewart have revised the quarterly EPS estimates for 2010 at Teva Pharmaceuticals Industries Ltd. (ADR) (NASDAQ: TEVA). The estimates have been revised by analysts after analyzing the timing of the company’s new product launches in 2010. However, the...
